Bursitis Of Shoulder — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for bursitis of shoulder. 6 active patents protecting 1 drugs from 0+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
6
Active US patents
56/100
Avg vulnerability
Annual revenue covered

Originators in Bursitis Of Shoulder

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating bursitis of shoulder. Each bar = one year. Y-axis scaled to peak year (6 patents).

6
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Indocin Sr
INDOMETHACIN
6 56 2030-04-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9089471 Indocin Sr method of use 68 2030-04-23
9089471 Indocin Sr method of use 68 2030-04-23
8734847 Indocin Sr formulation 53 2030-04-23
8734847 Indocin Sr formulation 53 2030-04-23
8992982 Indocin Sr formulation 48 2030-04-23
8992982 Indocin Sr formulation 48 2030-04-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8992982 Indocin Sr formulation 48 2030-04-23
8992982 Indocin Sr formulation 48 2030-04-23
8734847 Indocin Sr formulation 53 2030-04-23
8734847 Indocin Sr formulation 53 2030-04-23
9089471 Indocin Sr method of use 68 2030-04-23
9089471 Indocin Sr method of use 68 2030-04-23

Related